A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination with Rituximab in Patients with Non-Hodgkin's Lymphoma

Por Robertson, Michael J., Kline, Justin, Struemper, Herbert, Koch, Kevin M., Bauman, John W., Gardner, Olivia S., Murray, Sharon C., Germaschewski, Fiona, Weisenbach, Jill, Jonak, Zdenka, Toso, John F.
Publicado em 2013

Activity of the oral MEK inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

Por Borthakur, Gautam, Popplewell, Leslie, Boyiadzis, Michael, Foran, James, Platzbecker, Uwe, Vey, Norbert, Walter, Roland B., Olin, Rebecca, Raza, Azra, Giagounidis, Aristoteles, Al-Kali, Aref, Jabbour, Elias, Kadia, Tapan, Garcia-Manero, Guillermo, Bauman, John W., Wu, Yuehui, Liu, Yuan, Schramek, Dan, Cox, Donna S., Wissel, Paul, Kantarjian, Hagop
Publicado no Cancer (2016)